| P50 | author | Ulf Diczfalusy | Q42813198 |
| P2093 | author name string | A Sönnerborg | |
| | M Gisslén | |
| | V Ormaasen | |
| | L Bertilsson | |
| | Y Böttiger | |
| | L Flamholc | |
| | F Josephson | |
| P2860 | cites work | Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals | Q35579020 |
| | Metabolism of 4 beta -hydroxycholesterol in humans. | Q40723392 |
| | Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. | Q40784945 |
| | 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians | Q43944775 |
| | Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans | Q44085569 |
| | Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein | Q44406923 |
| | Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation | Q48567513 |
| | Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers | Q48705073 |
| | The oxysterols cholest-5-ene-3 beta,4 alpha-diol, cholest-5-ene-3 beta,4 beta-diol and cholestane-3 beta,5 alpha,6 alpha-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques | Q59307014 |
| | Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma | Q71131941 |
| | Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents | Q77542483 |
| | Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095) | Q79633442 |
| | Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects | Q80063643 |
| P433 | issue | 8 | |
| P304 | page(s) | 775-781 | |
| P577 | publication date | 2008-05-06 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels | |
| P478 | volume | 64 | |